Literature DB >> 16055059

Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.

S K E Koekkoek1, K Yamaguchi, B A Milojkovic, B R Dortland, T J H Ruigrok, R Maex, W De Graaf, A E Smit, F VanderWerf, C E Bakker, R Willemsen, T Ikeda, S Kakizawa, K Onodera, D L Nelson, E Mientjes, M Joosten, E De Schutter, B A Oostra, M Ito, C I De Zeeuw.   

Abstract

Absence of functional FMRP causes Fragile X syndrome. Abnormalities in synaptic processes in the cerebral cortex and hippocampus contribute to cognitive deficits in Fragile X patients. So far, the potential roles of cerebellar deficits have not been investigated. Here, we demonstrate that both global and Purkinje cell-specific knockouts of Fmr1 show deficits in classical delay eye-blink conditioning in that the percentage of conditioned responses as well as their peak amplitude and peak velocity are reduced. Purkinje cells of these mice show elongated spines and enhanced LTD induction at the parallel fiber synapses that innervate these spines. Moreover, Fragile X patients display the same cerebellar deficits in eye-blink conditioning as the mutant mice. These data indicate that a lack of FMRP leads to cerebellar deficits at both the cellular and behavioral levels and raise the possibility that cerebellar dysfunctions can contribute to motor learning deficits in Fragile X patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16055059     DOI: 10.1016/j.neuron.2005.07.005

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  185 in total

1.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  The metabotropic glutamate receptor activates the lipid kinase PI3K in Drosophila motor neurons through the calcium/calmodulin-dependent protein kinase II and the nonreceptor tyrosine protein kinase DFak.

Authors:  Curtis Chun-Jen Lin; James B Summerville; Eric Howlett; Michael Stern
Journal:  Genetics       Date:  2011-04-21       Impact factor: 4.562

Review 3.  The trouble with spines in fragile X syndrome: density, maturity and plasticity.

Authors:  C X He; C Portera-Cailliau
Journal:  Neuroscience       Date:  2012-04-20       Impact factor: 3.590

4.  Temporal patterns of inputs to cerebellum necessary and sufficient for trace eyelid conditioning.

Authors:  Brian E Kalmbach; Tatsuya Ohyama; Michael D Mauk
Journal:  J Neurophysiol       Date:  2010-05-19       Impact factor: 2.714

5.  Differential olivo-cerebellar cortical control of rebound activity in the cerebellar nuclei.

Authors:  Freek E Hoebeek; Laurens Witter; Tom J H Ruigrok; Chris I De Zeeuw
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-15       Impact factor: 11.205

6.  Dynamic changes in the cerebellar-interpositus/red-nucleus-motoneuron pathway during motor learning.

Authors:  Raudel Sánchez-Campusano; Agnès Gruart; José M Delgado-García
Journal:  Cerebellum       Date:  2011-12       Impact factor: 3.847

Review 7.  FMR1: a gene with three faces.

Authors:  Ben A Oostra; Rob Willemsen
Journal:  Biochim Biophys Acta       Date:  2009-02-21

Review 8.  LTD-like molecular pathways in developmental synaptic pruning.

Authors:  Claire Piochon; Masanobu Kano; Christian Hansel
Journal:  Nat Neurosci       Date:  2016-09-27       Impact factor: 24.884

9.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

Review 10.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.